1
|
Clausse V, Goloudina AR, Uyanik B, Kochetkova EY, Richaud S, Fedorova OA, Hammann A, Bardou M, Barlev NA, Garrido C, Demidov ON. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy. Cell Death Dis 2016; 7:e2195. [PMID: 27077811 PMCID: PMC4855675 DOI: 10.1038/cddis.2016.96] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2015] [Revised: 03/01/2016] [Accepted: 03/07/2016] [Indexed: 12/16/2022]
Abstract
Inactivation of p53 found in more than half of human cancers is often associated with increased tumor resistance to anti-cancer therapy. We have previously shown that overexpression of the phosphatase Wip1 in p53-negative tumors sensitizes them to chemotherapeutic agents, while protecting normal tissues from the side effects of anti-cancer treatment. In this study, we decided to search for kinases that prevent Wip1-mediated sensitization of cancer cells, thereby interfering with efficacy of genotoxic anti-cancer drugs. To this end, we performed a flow cytometry-based screening in order to identify kinases that regulated the levels of γH2AX, which were used as readout. Another criterion of the screen was increased sensitivity of p53-negative tumor cells to cisplatin (CDDP) in a Wip1-dependent manner. We have found that a treatment with a low dose (75 nM) of MK-1775, a recently described specific chemical inhibitor of Wee1, decreases CDDP-induced H2AX phosphorylation in p53-negative cells and enhances the Wip1-sensitization of p53-negative tumors. We were able to reduce CDDP effective concentration by 40% with a combination of Wip1 overexpression and Wee1 kinase inhibition. We have observed that Wee1 inhibition potentiates Wip1-dependent tumor sensitization effect by reducing levels of Hipk2 kinase, a negative regulator of Wip1 pathway. In addition, during CDDP treatment, the combination of Wee1 inhibition and Wip1 overexpression has a mild but significant protective effect in normal cells and tissues. Our results indicate that inhibition of the negative regulators of Wip1 pathway, Wee1 and Hipk2, in p53-negative tumors could potentiate efficiency of chemotherapeutic agents without concomitant increase of cytotoxicity in normal tissues. The development and clinical use of Wee1 and Hipk1 kinase chemical inhibitors might be a promising strategy to improve anti-cancer therapy.
Collapse
Affiliation(s)
- V Clausse
- INSERM UMR 866, Laboratoire d'excellence ARC, Dijon, France.,University of Burgundy, Dijon, France
| | - A R Goloudina
- INSERM UMR 866, Laboratoire d'excellence ARC, Dijon, France.,University of Burgundy, Dijon, France
| | - B Uyanik
- INSERM UMR 866, Laboratoire d'excellence ARC, Dijon, France.,University of Burgundy, Dijon, France
| | | | - S Richaud
- INSERM UMR 866, Laboratoire d'excellence ARC, Dijon, France.,University of Burgundy, Dijon, France
| | - O A Fedorova
- Institute of Cytology, RAS, St. Petersburg, Russia
| | - A Hammann
- INSERM UMR 866, Laboratoire d'excellence ARC, Dijon, France.,University of Burgundy, Dijon, France
| | - M Bardou
- INSERM UMR 866, Laboratoire d'excellence ARC, Dijon, France.,University of Burgundy, Dijon, France
| | - N A Barlev
- Institute of Cytology, RAS, St. Petersburg, Russia
| | - C Garrido
- INSERM UMR 866, Laboratoire d'excellence ARC, Dijon, France.,University of Burgundy, Dijon, France.,Anticancer Center Georges François Leclerc, Dijon, France
| | - O N Demidov
- INSERM UMR 866, Laboratoire d'excellence ARC, Dijon, France.,University of Burgundy, Dijon, France.,Institute of Cytology, RAS, St. Petersburg, Russia
| |
Collapse
|